report-image

Bladder Cancer Market Analysis by Type (Transitional Cell Bladder Cancer, Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Others), By Treatment (Surgery, Chemotherapy, Immunotherapy Radiation Therapy, Others), By Major Tests (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Bladder Ultrasound), By End-Users (Hospitals, Specialty Clinics, Others) and by Region: Global Forecast, 2024 - 2034

  • PUBLISHED ON
  • 2024-04-17
  • NO OF PAGES
  • 191
  • CATEGORY
  • Healthcare & Life Sciences

Market Overview

The Bladder Cancer market is predicted to develop at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2034, when it is projected to reach USD 536.25 Million, based on an average growth pattern. The market is estimated to reach a value of USD 339.13 Million in 2024.

 

SOURCE: We Market Research

The cells that line the bladder's interior are the source of bladder cancer. It is primarily transitional cell carcinoma, though it can also appear as adenocarcinoma or squamous cell carcinoma. Risk factors include age, gender, family history, chemical exposure, chronic bladder problems, and smoking. Blood in the urine, frequent urination, and pelvic pain are typical signs. Depending on the stage of the cancer, different treatments may be used, such as immunotherapy, radiation therapy, chemotherapy, or surgery. A better prognosis depends on early identification, which is typically achieved by routine tests for high-risk patients. Getting medical help as soon as symptoms appear improves bladder cancer treatment efficacy and overall results.

The bladder cancer market is expanding globally due to a number of causes are, growing incidence rates are driving up need for cutting-edge diagnostics and therapies, particularly among the elderly population. Personalized therapy and early diagnosis are being made possible by technological breakthroughs, especially in the areas of molecular diagnostics and imaging. Market expansion is further aided by rising healthcare spending, rising awareness, and screening programs. Furthermore, potential treatment alternatives are being offered by continuing research and development initiatives, particularly in the areas of immunotherapy and targeted treatments. When combined, these forces are reshaping the bladder cancer treatment landscape, fostering innovation, and enhancing patient outcomes.

Market Scope

Report Attributes

Description

Market Size in 2024

USD 339.13 Million

Market Forecast in 2034

USD 536.25Million

CAGR % 2024-2034

5.7%

Base Year

2023

Historic Data

2016-2022

Forecast Period

2024-2034

Report USP

 

Production, Consumption, company share, company heatmap, company production capacity, growth factors and more

Segments Covered

By Type, By Treatment, By Major Tests, By End-Users  and By Region

Regional Scope

North America, Europe, APAC, South America and Middle East and Africa

Country Scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria

 

Bladder Cancer Industry: Dynamics & Restrains


 Market opportunity:


 

 We Market Research: Bladder Cancer Dashboard

Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.


Bladder Cancer Segmentation

Market- By Type Analysis

By Type, the Bladder Cancer Market is Categories into Transitional Cell Bladder Cancer, Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Others. The Transitional Cell Bladder Cancer segment accounts for the largest share of around 72% in 2024.


Transitional Cell Bladder Cancer is primarily driven by smoking, occupational exposure to chemicals, chronic bladder irritation, genetic factors, age/gender, and exposure to aristolochic acid, leading to DNA damage and cancer development.

The following segments are part of an in-depth analysis of the global Bladder Cancer market:

Market Segments

 

By  Treatment

·         Surgery

·         Chemotherapy

·         Immunotherapy Radiation Therapy

·         Others

By  Major Tests

·         Cystoscopy

·         Biopsy

·         Urinalysis

·         Urine Cytology

·         Bladder Ultrasound

By  End-Users

·         Hospitals

·         Specialty Clinics

·         Others

 

Bladder Cancer Industry: Regional Analysis

North America Market Forecast

North America dominate the Bladder Cancer Market with the highest revenue generating market with share of more than 47%. High incidence linked to aging populations, a culture of extensive smoking, and well-established healthcare systems that allow for early detection and cutting-edge treatment options, which improve survival chances.


Asia Pacific Market Statistics

Asia Pacific region is the second largest market in Bladder Cancer, due to the Rising incidence driven on by increased smoking rates, exposure to environmental carcinogens (such as industrial pollution), and more information has increased the need for supportive care and effective bladder cancer therapies throughout the region.

Europe Market Forecasts

Europe is expected to be the fastest-growing regional segment of the Bladder Cancer market during the forecast period. In the Europe region, common smoking habits, an aging population at risk for cancer, exposure to industrial pollutants, well-established healthcare systems that enable early detection, sedentary lifestyles and diets, and possible genetic predispositions that contribute to the development of the disease are the main causes of bladder cancer in Europe.

Key Market Players 

·         Pfizer Inc.

·         Johnson & Johnson

·         Astellas Pharma Inc.

·         Eli Lilly and Company

·         GlaxoSmithKline plc

·         Bayer AG

·         Seattle Genetics Inc.

·         Sanofi S.A.

·         Novartis AG

·         Merck & Co. Inc.

·         Hoffmann-La Roche Ltd.

·         AstraZeneca PLC

             ·         Other

1.      Global Bladder Cancer Market Introduction and Market Overview

1.1.    Objectives of the Study

1.2.    Global Bladder Cancer Market Scope and Market Estimation

1.2.1. Global Bladder Cancer Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2034)

1.2.2. Global Bladder Cancer Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034

1.3.    Market Segmentation

1.3.1. Component of Global Bladder Cancer Market

1.3.2. Technology of Global Bladder Cancer Market

1.3.3. Major Tests of Global Bladder Cancer Market

1.3.4. Region of Global Bladder Cancer Market

2.      Executive Summary

2.1.    Global Bladder Cancer Market Industry Trends under COVID-19 Outbreak

2.1.1. Global COVID-19 Status Overview

2.1.2. Influence of COVID-19 Outbreak on Global Bladder Cancer Market Industry Development

2.2.    Market Dynamics

2.2.1. Drivers

2.2.2. Limitations

2.2.3. Opportunities

2.2.4. Impact Analysis of Drivers and Restraints

2.3.    Pricing Trends Analysis & Average Selling Prices (ASPs)

2.4.    Key Mergers & Acquisitions, Expansions, JVs, Funding / VCs, etc.

2.5.    Porter’s Five Forces Analysis

2.5.1. Bargaining Power of Suppliers

2.5.2. Bargaining Power of Buyers

2.5.3. Threat of Substitutes

2.5.4. Threat of New Entrants

2.5.5. Competitive Rivalry

2.6.    Value Chain / Ecosystem Analysis

2.7.    Russia-Ukraine War Impacts Analysis

2.8.    Economic Downturn Analysis

2.9.      Market Investment Opportunity Analysis (Top Investment Pockets), By Segments & By Region

3.      Global Bladder Cancer Market Estimates & Historical Trend Analysis (2019 - 2023)

4.      Global Bladder Cancer Market Estimates & Forecast Trend Analysis, by TYPE

4.1.    Global Bladder Cancer Market Revenue (US$ Mn) Estimates and Forecasts, by TYPE, 2019 to 2034

4.1.1. Transitional Cell Bladder Cancer

4.1.2. Superficial Bladder Cancer

4.1.3. Invasive Bladder Cancer

4.1.4. Squamous Cell Bladder Cancer

4.1.5. Others

5.      Global Bladder Cancer Market Estimates & Forecast Trend Analysis, by Treatment

5.1.    Global Bladder Cancer Market Revenue (US$ Mn) Estimates and Forecasts, by Treatment, 2019 to 2034

5.1.1. Surgery

5.1.2. Chemotherapy

5.1.3. Immunotherapy Radiation Therapy

5.1.4. Others

6.      Global Bladder Cancer Market Estimates & Forecast Trend Analysis, by Major Tests

6.1.    Global Bladder Cancer Market Revenue (US$ Mn) Estimates and Forecasts, by Major Tests, 2019 to 2034

6.1.1. Cystoscopy

6.1.2. Biopsy

6.1.3. Urinalysis

6.1.4. Urine Cytology

6.1.5. Bladder Ultrasound

7.      Global Bladder Cancer Market Estimates & Forecast Trend Analysis, by END-USERS

7.1.    Global Bladder Cancer Market Revenue (US$ Mn) Estimates and Forecasts, by Major Tests, 2019 to 2034

7.1.1. Hospitals

7.1.2. Specialty Clinics

7.1.3. Others

8.      Global Bladder Cancer Market Estimates & Forecast Trend Analysis, by Region

8.1.    Global Bladder Cancer Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2034

8.1.1. North America

8.1.2. Europe

8.1.3. Asia Pacific

8.1.4. Middle East & Africa

8.1.5. South America

9.      North America Bladder Cancer Market: Estimates & Forecast Trend Analysis

9.1.    North America Bladder Cancer Market Assessments & Key Findings

9.1.1. North America Bladder Cancer Market Introduction

9.1.2. North America Bladder Cancer Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

9.1.2.1.   By TYPE

9.1.2.2.   By Treatment

9.1.2.3.   By Major Tests

9.1.2.4.   By END-USERS

9.1.2.5.   By Country

9.1.2.5.1.     The U.S.

9.1.2.5.2.     Canada

9.1.2.5.3.     Mexico

10.  Europe Bladder Cancer Market: Estimates & Forecast Trend Analysis

10.1.  Europe Bladder Cancer Market Assessments & Key Findings

10.1.1.   Europe Bladder Cancer Market Introduction

10.1.2.   Europe Bladder Cancer Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

10.1.2.1.    By TYPE

10.1.2.2.    By Treatment

10.1.2.3.    By Major Tests

10.1.2.4.    By END-USERS

10.1.2.5.    By Country

10.1.2.5.1. Germany

10.1.2.5.2. U.K.

10.1.2.5.3. France

10.1.2.5.4. Italy

10.1.2.5.5. Spain

10.1.2.5.6. Russia

10.1.2.5.7. Rest of Europe

11.  Asia Pacific Bladder Cancer Market: Estimates & Forecast Trend Analysis

11.1.  Asia Pacific Market Assessments & Key Findings

11.1.1.   Asia Pacific Bladder Cancer Market Introduction

11.1.2.   Asia Pacific Bladder Cancer Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

11.1.2.1.    By TYPE

11.1.2.2.    By Treatment

11.1.2.3.    By Major Tests

11.1.2.4.    By END-USERS

11.1.2.5.    By Country

11.1.2.5.1. China

11.1.2.5.2. Japan

11.1.2.5.3. India

11.1.2.5.4. Australia

11.1.2.5.5. South Korea

11.1.2.5.6. ASEAN

11.1.2.5.7. Rest of Asia Pacific

12.  Middle East & Africa Bladder Cancer Market: Estimates & Forecast Trend Analysis

12.1.  Middle East & Africa Market Assessments & Key Findings

12.1.1.   Middle East & Africa Bladder Cancer Market Introduction

12.1.2.   Middle East & Africa Bladder Cancer Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

12.1.2.1.    By TYPE

12.1.2.2.    By Treatment

12.1.2.3.    By Major Tests

12.1.2.4.    By END-USERS

12.1.2.5.    By Country

12.1.2.5.1. U.A.E.

12.1.2.5.2. Saudi Arabia

12.1.2.5.3. Egypt

12.1.2.5.4. South Africa

12.1.2.5.5. Rest of Middle East & Africa

13.  South America Bladder Cancer Market: Estimates & Forecast Trend Analysis

13.1.  South America Market Assessments & Key Findings

13.1.1.   South America Bladder Cancer Market Introduction

13.1.2.   South America Bladder Cancer Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

13.1.2.1.    By TYPE

13.1.2.2.    By Treatment

13.1.2.3.    By Major Tests

13.1.2.4.    By END-USERS

13.1.2.5.    By Country

13.1.2.5.1. Brazil

13.1.2.5.2. Argentina

13.1.2.5.3. Colombia

13.1.2.5.4. Rest of South America

14.  Competition Landscape

14.1.  Global Bladder Cancer Market Competition Matrix & Benchmarking, by Leading Players / Innovators / Emerging Players / New Entrants

14.2.  Global Bladder Cancer Market Competition White Space Analysis, By Major Tests

14.3.  Global Bladder Cancer Market Competition Heat Map Analysis, By Major Tests

14.4.  Global Bladder Cancer Market Concentration & Company Market Shares (%) Analysis, 2022

15.  Company Profiles

15.1.                     Pfizer Inc.

15.1.1.   Company Overview & Key Stats

15.1.2.   Financial Performance & KPIs

15.1.3.   Product Portfolio

15.1.4.   Business Strategy & Recent Developments

* Similar details would be provided for all the players mentioned below 

15.2.      Johnson & Johnson

15.3.      Astellas Pharma Inc.

15.4.      Eli Lilly and Company

15.5.      GlaxoSmithKline plc

15.6.      Bayer AG

15.7.      Seattle Genetics Inc.

15.8.      Sanofi S.A.

15.9.      Novartis AG

15.10.  Merck & Co. Inc.

15.11.  Hoffmann-La Roche Ltd.

15.12.  AstraZeneca PLC

15.13.  Others

16.  Research Methodology

16.1.  External Transportations / Databases

16.2.  Internal Proprietary Database

16.3.  Primary Research

16.4.  Secondary Research

16.5.  Assumptions

16.6.  Limitations

16.7.  Report FAQs

17.  Research Findings & Conclusion

 

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process